联合雄激素阻断治疗晚期前列腺癌疗效观察  

Effect of combined Androgen blockade on advanced prostate cancer

作　　者：洪斌[1] 赵正平[1] 俞斌[1] 吴颂华[1] 施健[1] 

机构地区：[1]上海中医药大学附属普陀医院,上海200062

出　　处：《现代中西医结合杂志》2006年第20期2748-2749,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨联合雄激素阻断治疗晚期前列腺癌的疗效。方法选择38例晚期前列腺癌患者，明确诊断后口服Flutamid 250 mg．3次/d．3～7d后腹部皮下注射LHRHA3．6mg，3个月后再行去势手术，术后继续服用Flutamid。分析38例去势加雄激素阻断剂治疗晚期前列腺癌的临床资料。结果化学去势加雄激素阻断治疗3个月可筛选排除雄激素非依赖性前列腺癌，其后的手术去势加雄激素阻断治疗可维持稳定的去势水平。本组复发4例，复发率10％，5例出现肝功能异常。结论联合雄激素阻断治疗晚期前列腺癌安全有效。Objective It is to evaluate the efficacy of combined Androgen blockade on advanced prostate cancer. Methods 38 cases of patients with advanced prostate cancer were given Flutamid 250 mg for oral use three times every day after final diagnosis, and given LHRH A 3.6 mg 3 - 7 days later. After three months the patients were performed castration opera tion on and given Flutamid continually after the operation. The patients＇ clinical data was analyzed retrospectively, Results Hormone sensitive androgen independent prostate cancer （HRPC） can be excluded after medical castration plus androgen blocker for three months. After that, castrating level can be maintained by operative castration plus androgen blocker. The relapse rate was 10 % , 5 eases showed impaired liver function. Conclusion Combined Androgen blockade is safety and effective for the treatment of advanced prostate cancer.

关 键 词：前列腺癌 雄激素 去势 

分 类 号：R737.25[医药卫生—肿瘤]